TG Therapeutics (NASDAQ:TGTX) Shares Up 4.9% – What’s Next?

TG Therapeutics, Inc. (NASDAQ:TGTX)’s share price rose 4.9% on Tuesday . The company traded as high as $24.12 and last traded at $23.94. Approximately 1,291,632 shares changed hands during trading, a decline of 65% from the average daily volume of 3,677,023 shares. The stock had previously closed at $22.83.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. The Goldman Sachs Group boosted their price objective on TG Therapeutics from $18.00 to $20.00 and gave the company a “neutral” rating in a research report on Wednesday, August 7th. B. Riley boosted their price target on shares of TG Therapeutics from $29.00 to $34.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $49.00 price objective on shares of TG Therapeutics in a report on Wednesday, September 18th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $31.83.

TG Therapeutics Price Performance

The business has a fifty day moving average price of $23.12 and a 200 day moving average price of $19.26. The company has a debt-to-equity ratio of 0.58, a current ratio of 3.58 and a quick ratio of 2.83. The company has a market capitalization of $3.70 billion, a price-to-earnings ratio of 104.09 and a beta of 2.21.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.04 EPS for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.08. The company had revenue of $73.47 million for the quarter, compared to the consensus estimate of $65.92 million. TG Therapeutics had a net margin of 27.60% and a return on equity of 57.73%. TG Therapeutics’s revenue was up 357.0% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.34) EPS. On average, research analysts expect that TG Therapeutics, Inc. will post 0.13 earnings per share for the current fiscal year.

Institutional Investors Weigh In On TG Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. NBC Securities Inc. raised its stake in shares of TG Therapeutics by 58.9% in the 3rd quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 485 shares in the last quarter. Ashton Thomas Private Wealth LLC bought a new stake in TG Therapeutics in the second quarter worth about $35,000. ORG Wealth Partners LLC acquired a new stake in TG Therapeutics in the 3rd quarter valued at about $53,000. DekaBank Deutsche Girozentrale bought a new position in shares of TG Therapeutics during the 1st quarter valued at about $58,000. Finally, Lazard Asset Management LLC acquired a new position in shares of TG Therapeutics in the 1st quarter worth approximately $91,000. 58.58% of the stock is currently owned by institutional investors and hedge funds.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.